Log In
Print this Print this

dorgenmeltucel-L, HyperAcute Melanoma (NLG-12036)

  Manage Alerts
Collapse Summary General Information
Company NewLink Genetics Corp.
DescriptionAlpha 1,3-galactosyltransferase-expressing allogeneic melanoma tumor cell vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationMelanoma
Indication DetailsTreat advanced melanoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today